rs28929495
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We herein first report G719S mutation in lung adenocarcinoma with tonsillar metastasis.
|
29245278 |
2017 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Thus, this advanced EGFR-mutated NSCLC displayed very rapid onset and heterogeneous genetic and phenotypic mechanisms of TKI-resistance occurring at different times and locations of metastatic disease: concomitant FGFR3-mutation before and during TKI-treatment as potential intrinsic mechanism for the rapid progression; transformation to SCLC at first progression during TKI-therapy; acquired T790M EGFR-mutation at second progression.
|
29110841 |
2017 |
rs397517132
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The utility of immunohistochemistry (IHC) as an alternative approach for detection of BRAF(V600E) in the thoracic metastases of sporadic mCRC patients has not been evaluated until now.
|
24798160 |
2014 |
rs7795743
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The G allele in rs7795743 in EGFR had an OR for metastasis of 0.68 (p-value = 0.02) and hazard ratio (HR) for progression of 0.66 (p-value = 0.004).
|
30827726 |
2019 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients.
|
24789720 |
2014 |
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The 19del and L858R patients were similar regarding recurrent patterns, except on pleural/chest wall metastasis (26.0% vs. 12.2%, p = 0.007).
|
29026990 |
2018 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The 19del and L858R patients were similar regarding recurrent patterns, except on pleural/chest wall metastasis (26.0% vs. 12.2%, p = 0.007).
|
29026990 |
2018 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The 19del and L858R patients were similar regarding recurrent patterns, except on pleural/chest wall metastasis (26.0% vs. 12.2%, p = 0.007).
|
29026990 |
2018 |
rs121913444
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Pyrosequencing of the primary pancreatic tumor antecedent to metastasis showed an uncommon EGFR mutation at L861Q in the kinase domain of exon 21.
|
29695402 |
2018 |
rs2227983
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results show that, in patients with cervical cancer, the R497K polymorphism is correlated with treatment response and the risk of recurrence or metastasis.
|
31254173 |
2019 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Osimertinib is an oral, highly selective, irreversible inhibitor of both EGFR-activating mutations and the T790M-resistance mutation, while sparing the activity of wild-type EGFR This article reviews clinical trial development of osimertinib in patients with NSCLC, presenting efficacy and safety evidence for its value in the EGFR T790M mutation-positive population and in different settings, including patients with metastatic disease.
|
27784815 |
2016 |
rs397517132
|
|
|
0.030 |
GeneticVariation |
BEFREE |
On PTC univariate analysis, EGFR-H correlated with increasing stage, extrathyroid extension, tumor capsule invasion, adverse pathologic features (any demonstration of extrathyroid extension, tumor capsule invasion, lymphovascular invasion, lymph node metastasis, and/or distant metastasis), and BRAF(V600E) mutations.
|
23746767 |
2013 |
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas.
|
27039821 |
2016 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas.
|
27039821 |
2016 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas.
|
27039821 |
2016 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In addition, genomic rearrangements and late amplification of the EGFR gene likely induced by afatinib treatment following the acquisition of a T790M gefitinib resistance mutation provided further evidence to tie the time of metastasis formation to treatment history.
|
30694556 |
2019 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In a subgroup of patients with intrathoracic metastatic disease (M0/M1a; n = 21), the sensitivity increased from 26% to 74% for activating mutations (P = 0.003) and from 19% to 31% for T790M (P = 0.5) when using exoNA for detection.
|
29216356 |
2018 |
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival.
|
28745320 |
2017 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival.
|
28745320 |
2017 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival.
|
28745320 |
2017 |
rs723526
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, in a meta-analysis, 3 additional SNPs were significantly associated with SLN metastasis (EGFR rs723526 and TLR3 rs3775292) and melanoma-specific death (TLR3 rs7668666).
|
23462921 |
2013 |
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed).
|
22285168 |
2012 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed).
|
22285168 |
2012 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed).
|
22285168 |
2012 |
rs397517132
|
|
|
0.030 |
GeneticVariation |
BEFREE |
BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a marker of resistance to anti-EGFR therapy in metastatic disease.
|
23650027 |
2013 |